uniQure N.V. Ordinary Shares Share Price
NASDAQ: QURE | Mid CapuniQure N.V. Ordinary Shares Stock Performance
Open $44.09 | Prev. Close $45.10 | Circuit Range N/A |
Day Range $43.91 - $45.45 | Year Range $8.74 - $71.49 | Volume 57,951 |
Average Traded $44.66 |
uniQure N.V. Ordinary Shares Share Price Today
As of 9 August 2026, uniQure N.V. Ordinary Shares's share price is $46.38. The stock opened at $44.09, compared to its previous close of $45.10. During today's trading session, uniQure N.V. Ordinary Shares's share price traded between $43.91 and $45.45, with an average price of $44.68. Over the past 52 weeks, the stock has recorded a high of $71.49 and a low of $8.74. In terms of performance, uniQure N.V. Ordinary Shares's share price has risen by 197.78% over the last six months and is up 183.84% on a year-on-year basis.
uniQure N.V. Ordinary Shares Share Price Chart
uniQure N.V. Ordinary Shares Stock Fundamentals & Key Indicators
Market Cap $2.67B | PE Ratio (TTM) -13.40 | Dividend Yield N/A |
EPS (TTM) $-3.46 | Revenue (TTM) $16.10M | Return On Equity (TTM) -100.04% |
Profit Margin -1236.00% | Debt to Equity 0.32 | Quarterly Earnings Growth YoY N/A |
uniQure N.V. Ordinary Shares Quarterly Profit & Loss
All figures in USD
uniQure N.V. Ordinary Shares Annual Profit & Loss
All figures in USD
About uniQure N.V. Ordinary Shares
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V. Ordinary Shares Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $43.19 | $44.26 | +1.39% |
Jul 2026 | $46.15 | $43.65 | -5.16% |
Jun 2026 | $27.66 | $46.02 | +61.43% |
May 2026 | $19.84 | $28.51 | +42.94% |
Apr 2026 | $17.53 | $19.95 | +22.06% |
Mar 2026 | $9.22 | $16.34 | +4.91% |
Feb 2026 | $22.67 | $15.57 | -31.45% |
Jan 2026 | $23.91 | $22.72 | -4.90% |
Dec 2025 | $26.64 | $23.89 | -13.03% |
Nov 2025 | $23.05 | $27.47 | -59.41% |
Oct 2025 | $57.85 | $67.68 | +15.91% |
Sep 2025 | $16.16 | $58.39 | +257.34% |
QURE Share Price FAQs
What is uniQure N.V. Ordinary Shares share price today?
What is the 52 week high and 52 week low of uniQure N.V. Ordinary Shares stock?
What is QURE's market capitalisation today?
What is QURE's net income for the last quarter?
What is the 5 year returns of QURE?
What is the high & low stock price of QURE today?
Can I buy QURE shares in India?